Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Organoid-based colorectal tumor microenvironment model for immuno-oncology research

Created on 06 Jun 2026

Authors

Filip, A. M., Cubela, I., Lavickova, B., Coto-Llerena, M., Danenberg, E., Daniel, M., Ehret, B., Chevrier, S., Kromer, K., Harter, M. F., Lukonin, I., Jin, W., Jean-Mairet, P., Cremasco, F., Colombetti, S., Cabon, L., Gjorevski, N.

Abstract

The development of cancer immunotherapies is hindered by the lack of human-relevant models that accurately translate to patient outcomes. We combine patient-derived colorectal tumor organoids (PDOs) and cancer-associated fibroblasts (CAFs) into floating extracellular matrix drops to form miniature colorectal tumors. These SHaking Organoid COcultures (SHOCOs) maintain immune cells in numbers, states and functional interactions that are more physiologically accurate than traditional PDO-based co-culture models. Immunocompetent SHOCOs treated with T-cell bispecific antibodies exhibited a robust anti-tumor response, in a concentration- and duration of treatment-dependent manner. By varying the stromal content, we found that fibroblasts present a physical barrier that hinders intratumoral T-cell infiltration. We also demonstrate that tumor-associated stroma can be exploited therapeutically in potentiating anti-tumor immune responses. SHOCOs could aid the battle against cancer both by providing fundamental insights into immune and stromal tumor biology, and by catalyzing the discovery of novel therapeutic approaches.

Preprint server: bioRxiv
The authors list and abstract were imported from bioRxiv on 06 Jun 2026.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this preprint? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 15
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement